April 30, 2020

Successful manufacturing of clinical-grade SARS-CoV-2 specific T Cells for adoptive cell therapy

Category: Article Summary

Topic: Testing and Treatment

• Leung et al. demonstrate that clinical-grade SARS-CoV-2 specific T cells can be isolated from the blood of convalescent donors rapidly and efficiently using SARS-CoV-2 specific peptides and an automated medical device expedient for emergent treatment of severe COVID-19 disease until effective vaccines or treatment are developed. 

Leung et al. (Apr 30, 2020). Successful manufacturing of clinical-grade SARS-CoV-2 specific T Cells for adoptive cell therapy. Pre-print downloaded Apr 30 from https://doi.org/10.1101/2020.04.24.20077487